tetano
Editor, Senior Moderator
Am J Emerg Med
. 2022 Mar 13;S0735-6757(22)00161-9.
doi: 10.1016/j.ajem.2022.03.005. Online ahead of print.
Posterior reversible encephalopathy syndrome - A pathology that should not be overlooked in the era of COVID-19: Case report
Patricia Ioan[SUP] 1 [/SUP], Athena Cristina Ribigan[SUP] 2 [/SUP], Octaviana Rusu[SUP] 1 [/SUP], Ionut Flavius Bratu[SUP] 1 [/SUP], Raluca Stefania Badea[SUP] 3 [/SUP], Florina Antochi[SUP] 1 [/SUP]
Affiliations
Abstract
Background and objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) that causes Coronavirus Disease 2019 (COVID-19) may determine a series of neurological complications directly, by invasion of the nervous system or indirectly, secondary to systemic organ failure. Posterior reversible encephalopathy syndrome (PRES) represents a clinical and radiological neurological entity involving predominantly the occipital lobes. PRES was observed in patients receiving cytotoxic drugs, patients suffering from infectious diseases and sepsis, hypertensive emergencies and eclampsia, renal or autoimmune diseases. As more infectious SARS-COV-2 variants are now dominant in most of the Europe, an increasing number of patients is presenting to the Emergency Department.
Materials and methods: Case report of a 38-year-old patient, with previous exposure to SARS-COV-2 presented to the Emergency Department (ED) with generalized tonic-clonic seizures, dyspnea, cortical blindness and aphasia. The patient had been exhibiting fever, cough and shortness of breath in the previous 10 days. He had no relevant medical history and was receiving antibiotics and corticosteroids as prescribed by his general practitioner.
Results: Laboratory findings together with the thoracic computed tomography scan were consistent with the diagnosis of severe SARS-COV-2 pneumonia. The cerebral MRI scans showed bilateral T2-weighted/FLAIR hyperintensities that were suggestive for PRES. The patient was diagnosed with COVID-19 complicated with PRES. He received adequate treatment and the symptoms resolved in 48 h.
Conclusions: This is a rare and interesting case of a patient with PRES and COVID-19 as underlying pathology, in whom rapid diagnosis in the ED and early initiation of appropriate treatment led to full recovery. Immediate extensive work-up in patients with COVID-19 and neurological symptoms proves to be paramount for best outcome. To our knowledge this is the first case of PRES described in a patient with Delta variant of SARS-COV-2.
Keywords: COVID-19; PRES; Posterior reversible encephalopathy syndrome; SARS-COV-2; delta variant.
. 2022 Mar 13;S0735-6757(22)00161-9.
doi: 10.1016/j.ajem.2022.03.005. Online ahead of print.
Posterior reversible encephalopathy syndrome - A pathology that should not be overlooked in the era of COVID-19: Case report
Patricia Ioan[SUP] 1 [/SUP], Athena Cristina Ribigan[SUP] 2 [/SUP], Octaviana Rusu[SUP] 1 [/SUP], Ionut Flavius Bratu[SUP] 1 [/SUP], Raluca Stefania Badea[SUP] 3 [/SUP], Florina Antochi[SUP] 1 [/SUP]
Affiliations
- PMID: 35346531
- DOI: 10.1016/j.ajem.2022.03.005
Abstract
Background and objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) that causes Coronavirus Disease 2019 (COVID-19) may determine a series of neurological complications directly, by invasion of the nervous system or indirectly, secondary to systemic organ failure. Posterior reversible encephalopathy syndrome (PRES) represents a clinical and radiological neurological entity involving predominantly the occipital lobes. PRES was observed in patients receiving cytotoxic drugs, patients suffering from infectious diseases and sepsis, hypertensive emergencies and eclampsia, renal or autoimmune diseases. As more infectious SARS-COV-2 variants are now dominant in most of the Europe, an increasing number of patients is presenting to the Emergency Department.
Materials and methods: Case report of a 38-year-old patient, with previous exposure to SARS-COV-2 presented to the Emergency Department (ED) with generalized tonic-clonic seizures, dyspnea, cortical blindness and aphasia. The patient had been exhibiting fever, cough and shortness of breath in the previous 10 days. He had no relevant medical history and was receiving antibiotics and corticosteroids as prescribed by his general practitioner.
Results: Laboratory findings together with the thoracic computed tomography scan were consistent with the diagnosis of severe SARS-COV-2 pneumonia. The cerebral MRI scans showed bilateral T2-weighted/FLAIR hyperintensities that were suggestive for PRES. The patient was diagnosed with COVID-19 complicated with PRES. He received adequate treatment and the symptoms resolved in 48 h.
Conclusions: This is a rare and interesting case of a patient with PRES and COVID-19 as underlying pathology, in whom rapid diagnosis in the ED and early initiation of appropriate treatment led to full recovery. Immediate extensive work-up in patients with COVID-19 and neurological symptoms proves to be paramount for best outcome. To our knowledge this is the first case of PRES described in a patient with Delta variant of SARS-COV-2.
Keywords: COVID-19; PRES; Posterior reversible encephalopathy syndrome; SARS-COV-2; delta variant.